Literature DB >> 2713503

A C----T substitution at nt--101 in a conserved DNA sequence of the promotor region of the beta-globin gene is associated with "silent" beta-thalassemia.

J M Gonzalez-Redondo1, T A Stoming, A Kutlar, F Kutlar, K D Lanclos, E F Howard, Y J Fei, M Aksoy, C Altay, A Gurgey.   

Abstract

Sequence analyses and dot-blot analyses with synthetic oligonucleotide probes have identified eight individuals in three Turkish families and one Bulgarian family with one chromosome having a C----T mutation at nucleotide position--101 relative to the Cap site of the beta-globin gene. This nucleotide is part of one of the conserved blocks of nucleotides within the promoter region; in vitro expression analyses with the chloramphenicol acetyltransferase system showed that this substitution will decrease the effectiveness of transcription. Five subjects had a thalassemia intermedia due to the additional presence of a known classical high hemoglobin (Hb) A2 beta-thalassemia mutation on the second chromosome; their hematologic condition was relatively mild. The three persons with a heterozygosity for the--101 C----T mutation had normal hematologic data without microcytosis but with high-normal levels of Hb A2 and a mild imbalance in chain synthesis. The newly discovered mutation is considered one of the silent types of beta-thalassemia. It is relatively rare because it was absent among several hundred normal and beta-thalassemia chromosomes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713503

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  The molecular basis of beta-thalassemia in Turkey.

Authors:  A N Başak; H Ozçelik; A Ozer; A Tolun; M Aksoy; L Ağaoğlu; F Ridolfi; L Ulukutlu; N Akar; A Gürgey
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

2.  Fetal hemoglobin in normal adults and beta-thalassemia heterozygotes.

Authors:  A Kutlar; F Kutlar; L G Gu; S M Mayson; T H Huisman
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

3.  A Czechoslovakian teenager with Hb E-beta zero-thalassemia [IVS-I-1 (G----A)] complicated by the presence of an alpha-globin gene triplication.

Authors:  K Indrak; Y J Fei; H W Li; E Baysal; V Brabec; H Fortova; J Cermak; T H Huisman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

4.  The epidemiology of abnormal hemoglobins in Mediterranean high-level athletes.

Authors:  Imed Touhami; Slaheddine Fattoum; Amina Bibi; Hajer Siala; Taieb Messaoud; Donia Koubaa; Rafik Mankai; Zakia Bartagi; Daniel Le Gallais
Journal:  Eur J Appl Physiol       Date:  2009-12-16       Impact factor: 3.078

5.  Effect of alpha thalassaemia trait and enhanced gamma chain production on disease severity in beta thalassaemia major and intermedia.

Authors:  P Gringras; B Wonke; J Old; A Fitches; D Valler; A M Kuan; V Hoffbrand
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

6.  Discrimination among potential activators of the beta-globin CACCC element by correlation of binding and transcriptional properties.

Authors:  G A Hartzog; R M Myers
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

7.  Guidelines for the fetal diagnosis of globin gene disorders. Globin Gene Disorder Working Party of the BCSH General Haematology Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

8.  Clinical heterogeneity of silent-gene b-thalassemia among Indians.

Authors:  A Nadkarni; A Pawar; V C Mudera; D Mohanty; R Colah
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

Review 9.  The prevention of thalassemia.

Authors:  Antonio Cao; Yuet Wai Kan
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

10.  Silent carrier beta-thalassaemia due to a severe beta-globin mutation interacting with other genetic elements.

Authors:  D Rund; D Filon; A Oppenheim; A Abramov
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.